Drug Profile


Alternative Names: JBM-TC-4

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Joben Bio-Medical
  • Class Herbal medicines; Ketones; Lactams; Skin disorder therapies; Spiro compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Radiodermatitis

Most Recent Events

  • 04 Apr 2017 Phase-II development for Radiodermatitis (Treatment and Prevention in breast cancer patients) is ongoing in Taiwan (PO)
  • 01 Nov 2014 Phase-II clinical trials in Radiodermatitis (Treatment and Prevention) in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top